CellCentric Raises $220M for Multiple Myeloma Drug Development

CellCentric has successfully closed an oversubscribed $220 million Series D financing, a significant capital infusion aimed at propelling its lead candidate, inobrodib, through pivotal late-stage clinical trials for multiple myeloma. The substantial funding round underscores strong investor confidence in the company's novel p300/CBP inhibitor, a first-in-class oral therapy designed to address critical unmet needs in the hematologic oncology space.

The financing was spearheaded by specialist healthcare investor Venrock Healthcare Capital Partners. A robust syndicate of both new and existing backers participated, including Fidelity Management & Research Company, Sofinnova Partners, HBM Healthcare, RA Capital Management, Forbion, Pfizer, Avego BioScience Capital, and the American Cancer Society BrightEdge. This broad support highlights a collective belief in inobrodib's therapeutic potential, particularly in challenging relapsed and refractory multiple myeloma patient populations.

Proceeds from this Series D round are earmarked for advancing inobrodib into registration-enabling studies. Specifically, the capital will support continued enrollment in the ongoing Phase 2 DOMMINO-1 trial and the initiation of the global Phase 3 DOMMINO-2 study in the latter half of 2026. Furthermore, the funding will facilitate the exploration of inobrodib in additional combination regimens and maintenance therapy settings, expanding its potential application across the multiple myeloma treatment continuum.

Inobrodib has demonstrated promising clinical activity, notably in combination with pomalidomide and dexamethasone (InoPd). Data presented in late 2025 indicated that a 20 mg dose of inobrodib in this triplet regimen achieved response rates at least double those seen with historical therapies in heavily pretreated patients with relapsed or refractory multiple myeloma, who had received a median of five prior treatment lines. This efficacy, coupled with a manageable safety profile, positions inobrodib as a potentially valuable oral option for patients with limited therapeutic alternatives.

The multiple myeloma market is a dynamic and competitive arena, with significant advancements in recent years driven by novel agents like bispecific T cell engagers and anti-BCMA therapies. However, a substantial portion of patients eventually relapse or become refractory to existing treatments, creating a persistent demand for innovative therapeutic strategies. Inobrodib's oral administration offers a distinct advantage in convenience and patient experience, potentially simplifying treatment protocols and improving quality of life.

Will West, Ph.D., CEO of CellCentric, expressed enthusiasm for the investor backing, emphasizing inobrodib's potential to offer a fresh therapeutic avenue, especially for patients who have progressed on or are ineligible for newer, more intensive treatments. The company is focused on completing the registration-enabling studies for the all-oral triplet, aiming to bring a transformative treatment to patients facing this challenging disease. The prior granting of Fast Track and Orphan Drug designations by the FDA for inobrodib in RRMM further underscores its potential to address a significant unmet medical need.